About Tissue Genesis
Tissue Genesis is a company based in Honolulu (United States) founded in 2001 was acquired by Orgenesis in October 2020. Tissue Genesis has raised $22.14 million across 12 funding rounds from investors including Orgenesis and Military Health. The company has 5 employees as of December 31, 2022. Tissue Genesis offers products and services including Icellator 2 and Cell Icellation Kit. Tissue Genesis operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and ViaCyte, among others.
- Headquarter Honolulu, United States
- Employees 5 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tissue Genesis, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tissue Genesis
Tissue Genesis offers a comprehensive portfolio of products and services, including Icellator 2 and Cell Icellation Kit.
Automated system for extracting stem cells from adipose tissue quickly.
Sterile kit for efficient stem cell isolation and processing.
Funding Insights of Tissue Genesis
Tissue Genesis has successfully raised a total of $22.14M across 12 strategic funding rounds. The most recent funding activity was a Series A round of $500 thousand completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tissue Genesis
Tissue Genesis has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Orgenesis and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked | |
|
Cell and gene therapies for multiple disorders are developed.
|
Locked | Locked | Locked |
Investor details for Tissue Genesis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tissue Genesis
Investment portfolio details for Tissue Genesis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tissue Genesis
Detailed financials for Tissue Genesis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tissue Genesis Comparisons
Peer comparison for Tissue Genesis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tissue Genesis
Tissue Genesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and ViaCyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
Detailed competitors of Tissue Genesis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tissue Genesis
Complete news archive for Tissue Genesis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tissue Genesis
Tissue Genesis was founded in 2001 and raised its 1st funding round 8 years after it was founded.
Tissue Genesis is headquartered in Honolulu, United States. It is registered at Honolulu, Hawaii, United States.
Tissue Genesis is a funded company, having raised a total of $22.14M across 12 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Tissue Genesis is 5.
Tissue Genesis develops stem cell therapeutics for tissue healing. Its proprietary platform technology Icellator Cell Isolation System isolates stem cells from the patients adipose tissue. In addition, the company also develops Adipase, designed to optimize the isolation process of the Icellator. Tissue Genesis is currently conducting clinical trials for the use of stem cells in peripheral vascular disease and erectile dysfunction.
Tissue Genesis's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Tissue Genesis offers Icellator 2 and Cell Icellation Kit.
Tissue Genesis has 2 investors. Key investors include Orgenesis, and Military Health.